510(k) Report

510(k) · Cleared

Cleared

Clever Choice Auto-Code Pro Blood Glucose Monitoring System Model TD-4267

K093506510(k) SpecialCleared Apr 1, 2010140-day reviewClass II21 CFR 862.1345

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Taidoc Technology Corporation · CGA Glucose Oxidase, Glucose

Cleared on Apr 1, 2010 as substantially equivalent to K090187 (Taidoc Technology Corporation, 2009) after a 140-day review. Its family tree reaches back 2 generations to 2007.

Decided
Apr 1, 2010
Review
140 days
Class
Class II
Product code
CGA
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K070472 (2007). No later device cites it as a predicate yet.

  1. Root · 2 generations backK070472 Clever Chek TD-4230 Blood Glucose Monitoring System, RD-4230…Taidoc Technology Corporation · 2007
  2. 1 generation backK090187 Fora G30 Blood Glucose Monitoring System, Model TD-4241Taidoc Technology Corporation · 2009
  3. This deviceK093506 Clever Choice Auto-Code Pro Blood Glucose Monitoring System Model…Taidoc Technology Corporation · 2010
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K070472Clever Chek TD-4230 Blood Glucose Monitoring System, RD-4230, Surechek Blood…Taidoc Technology Corporation2007—
−1K090187Fora G30 Blood Glucose Monitoring System, Model TD-4241Taidoc Technology Corporation2009—
0 (this device)K093506Clever Choice Auto-Code Pro Blood Glucose Monitoring System Model TD-4267Taidoc Technology Corporation2010—
FIG. 1 — Lineage of K093506, 2007–2010Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CGA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CGA device

  1. #1 K252488 ABL90 FLEX PLUS Systemscore 12.8 · 6 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K090187Fora G30 Blood Glucose Monitoring System, Model TD-4241
Summary page 1
…ring System Common/Usual Name: Blood Glucose Test System Manufacturer TaiDoc Technology Corporation 510 (k) Number K090187 4. Device Description The CLEVER CHOICE Auto-Code Pro Blood Glucose Monitoring System is designed to quantitatively measure the…
Taidoc Technology Corporation2009—

Also cleared against K090187: 7 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 3 years and passes through 1 company; a new generation was cleared every 2.2 years on median.
  • None of the 2 ancestors has a recall.
  • 7 other devices also cite its predicate K090187.

How does its category compare?

All CGA devices

CGA Glucose Oxidase, Glucose: FDA decisions, review times, recalls and adverse event reports over 20 years. 2010, this device’s year, is highlighted.

FDA decisions per year · CGA

2in 2024

2007: 72008: 62009: 102010: 82011: 92012: 102013: 32014: 52015: 42016: 42017: 22018: 22019: 22020: 22021: 12022: 12023: 42024: 22026 (partial year): 1
2007high 10 (2009) · low 0 (2025)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CGA

249in 2023

2007: 122 days median2008: 56 days median2009: 155 days median2010: 122 days median2011: 217 days median2012: 123 days median2013: 441 days median2014: 265 days median2015: 150 days median2016: 157 days median2023: 249 days median
2007high 441 (2013) · low 56 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CGA

3in 2023

2007: 22008: 22009: 42010: 62011: 32013: 32014: 22015: 6, 2 Class I2016: 22019: 12023: 3
2007high 6 (2010) · low 0 (2012)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · CGA

59in 2025

2007: 292008: 372009: 752010: 1722011: 4232012: 2332013: 1722014: 1222015: 1552016: 362017: 922018: 692019: 1162020: 682021: 482022: 2722023: 1,1412024: 2662025: 59
2007high 1,141 (2023) · low 29 (2007)2025

MAUDE reports naming product code CGA, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20077122229
2008656237
200910155475
201081226172
201192173423
2012101230233
201334413172
201452652122
201541506 (2)155
20164157236
20172—092
20182—069
20192—1116
20202—068
20211—048
20221—0272
2023424931,141
20242—0266
20250—059
20261—0—

What is it indicated for?

The CLEVER CHOICE Auto-Code Pro Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood samples from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not…

Read the full statement (113 words)

The CLEVER CHOICE Auto-Code Pro Blood Glucose Monitoring System is intended

for use in the quantitative measurement of glucose in fresh capillary whole blood

samples from the finger and the following alternative sites: the palm, the forearm, the

upper-arm, the calf and the thigh. It is intended for use by healthcare professionals

and people with diabetes mellitus at home as an aid in monitoring the effectiveness of

diabetes control program. It is not intended for the diagnosis of or screening for

diabetes mellitus.

The CLEVER CHOICE Auto-Code Pro Blood Glucose Monitoring System cannot be

used on neonates.

The alternative site testing in above systems can be used only during steady-state

blood glucose conditions.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K093506: Clever Choice Auto-Code Pro Blood Glucose Monitoring System Model TD-4267.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K093506

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026